Hyperfine (HYPR) EBT Growth (1y) (2022 - 2026)
Hyperfine (HYPR) EBT Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -18.50% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 11.26% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 45.44% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 44.35% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 5.78% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 74.66% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 103.34% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -27.02% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Hyperfine | 92.81 Mn | 51.53 Mn | 1.98 Mn | 8.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.44% |
| Dec 31, 2025 | 43.10% |
| Sep 30, 2025 | -6.71% |
| Jun 30, 2025 | 9.17% |
| Mar 31, 2025 | 4.37% |
| Dec 31, 2024 | 2.75% |
| Sep 30, 2024 | 4.01% |
| Jun 30, 2024 | 4.52% |
| Mar 31, 2024 | 19.01% |
| Dec 31, 2023 | 18.19% |
| Sep 30, 2023 | 18.33% |
| Jun 30, 2023 | 54.07% |
| Mar 31, 2023 | 48.85% |
| Dec 31, 2022 | 49.94% |
| Sep 30, 2022 | 19.65% |
| Jun 30, 2022 | -58.84% |
| Mar 31, 2022 | -205.04% |